Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, As A Single Agent And In Combination With Either PF-06801591 Or Lenalidomide In Relapse/ Refractory Multiple Myeloma

Open to people ages 18 years and up

• Relapsed/refractory multiple myeloma
• Progressed or are intolerant of established therapies including proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody
• Performance Status of 0- 2 (unless due to bone pain)
• Adequate bone marrow, hematological, kidney and liver function
• Resolved acute effects of any prior therapy to baseline severity
• Not pregnant

• Recent history of other malignancies
• History of active autoimmune disorders
• Any form of primary immunodeficiency
• Active and clinically significant bacterial, fungal, or viral infection
• Evidence of active mucosal or internal bleeding
• History of severe immune-mediated adverse event with prior immunomodulatory treatment
• Major surgery within 4 weeks of study treatment start
• Radiation therapy within 2 weeks of study treatment start
• History of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment
• Donor Lymphocyte Infusion (DLI) within 30 days prior to study entry
• Less than 30 days since last dose of antibody based therapies or less than 5 half-lives since last dose of previous therapy
• Requirement for systemic immune suppressive medication
• Current requirement for chronic blood product support